Medical device classification: class 1, 2 and 3 under the FDA, EU and MHRA rules

A medical device’s class sets its route to market. In the US, the class decides whether the device needs a premarket notification (510(k)), a De Novo request or premarket approval. In the EU and Great Britain, it decides whether a notified body or an approved body must assess the device before it goes on sale. A wrong class puts a device on the wrong route: the US Food and Drug Administration (FDA) says a class III device that fails to meet premarket approval requirements “is considered to be adulterated under section 501(f) of the FD&C Act and may not be marketed”.

All three systems set the class from the device’s intended purpose and its risk. The FDA uses three classes, from class I, often written class 1, with the lowest risk, to class III, or class 3, with the greatest, in the agency’s words. The EU Medical Device Regulation (MDR) and Great Britain’s rules, which the Medicines and Healthcare products Regulatory Agency (MHRA) enforces, use four: I, IIa, IIb and III. Each market has its own rules, so one device can be in a different class in each.

All three classifications start from the same intended purpose and facts, so a maker can classify a device for the three markets at once. A device CE marked under the EU MDR can also go on sale in Great Britain on its EU class and route until 30 June 2030, and on 21 October 2026 the government said it “intends to proceed with legislative changes to indefinitely recognise CE marked medical devices certified under EU MDR and EU IVDR”. This guide quotes each system’s rules, shows where they differ and sets out what each class requires and costs.

Medical device classes at a glance: what class 1, 2 and 3 mean in each market

The EU and Great Britain divide the middle of the range into class IIa and class IIb.

ClassIn plain wordsExamples from the US regulationsUS routeEU and Great Britain route
IThe lowest risk, in the FDA’s words; “generally regarded as low risk” (MHRA)Manual toothbrush (872.6855); tongue depressor (880.6230)General controls; most need no 510(k)The maker declares conformity itself. An outside body checks only sterile or measuring aspects and, in the EU, the reuse of surgical instruments
II in the US; IIa and IIb in the EU and Great BritainBetween the two. The MHRA’s borderline guidance calls class IIa “lower medium risk” and class IIb “higher medium risk”Clinical mercury thermometer (880.2920); medical image management and processing system (892.2050)General and special controls; most need a 510(k), which shows the device is substantially equivalent to one already legally on the marketA notified body (EU) or an approved body (Great Britain) checks the device before sale. In the EU it audits the quality management system and assesses the technical documentation of representative devices, and of every class IIb implant except those Article 52(4) lists
IIIThe greatest risk, in the FDA’s words; “generally regarded as high risk” (MHRA)Implantable pacemaker pulse generator (870.3610); silicone gel-filled breast prosthesis (878.3540)Premarket approval, for mostA notified body or an approved body assesses the device itself: its technical documentation (EU) or its design dossier (Great Britain), or a type examination

Four devices and their class in the US, the EU and Great Britain

The table applies each system’s rules to four kinds of device, to show how far the classes can differ. It is our reading of the rules. Classify your own device from its intended purpose, with the steps below.

DeviceUSEUGreat Britain
Hip replacement, metal and polymer, for use with bone cementClass II (888.3350)Class III: total or partial joint replacements (rule 8)Class III: hip replacements (Directive 2005/50/EC)
Silicone gel-filled breast implantClass III (878.3540)Class III: breast implants (rule 8)Class III (Directive 2003/12/EC)
Implantable pacemaker pulse generatorClass III (870.3610)Class III: active implantable devices (rule 8)Outside the four classes: Part III of the UK MDR 2002 covers active implantable devices
Software that gives information used to take diagnostic or therapeutic decisionsThe class in its classification regulation; for example, a medical image management and processing system is class II (892.2050)Class IIa at least; IIb or III by the harm the decisions could cause (rule 11)No software rule; stand-alone software counts as an active device (Section 1.4). Class IIa under rule 10 if it allows direct diagnosis or monitoring of vital physiological processes, IIb if it monitors vital parameters where variations could mean immediate danger, otherwise class I (rule 12)

How to classify one device for the US, EU and UK markets

Each system starts from the same question: what is the device for? These steps take one device through all three and leave a record that an FDA reviewer, a notified body or an approved body can follow.

1. Confirm which rules cover the device. In the EU and Great Britain, in vitro diagnostic devices have their own classes. In Great Britain, active implantable devices are outside the four classes: Part III of the Medical Devices Regulations 2002 (the UK MDR 2002) covers them. Products incorporating or derived from human tissues or cells are outside the UK MDR 2002 (regulation 3(d)).

2. Write the intended purpose once. Use the same words on the label, in the instructions for use, in promotional material and in the clinical evaluation. All three systems read the class from it, and the US also counts indications for use given orally during a sale.

3. Record the facts the rules depend on. How long the device stays in continuous use; whether it enters the body, and how; whether it is an implant; whether it runs on energy; and whether it contains software, a medicinal substance, tissues or cells, or nanomaterial.

4. Find the US class. Match the intended use to a classification regulation in Parts 862 to 892, and read its class, exemptions and .9 limits. With no match and no legally marketed device to compare it with, plan a De Novo request or premarket approval.

5. Find the EU class. Test every rule in Annex VIII and take the highest class (Section 3.5).

6. Find the GB class. Test every rule in Annex IX, with Directives 2003/12/EC and 2005/50/EC, and take the highest class (Section 2.5). For a device you place in Great Britain on its CE marking under the EU MDR, the EU class sets the route until 30 June 2030.

7. Write down each result. Give the class, the rule or regulation behind it and the reason, and keep it with the technical documentation (EU: Annex II, Section 1.1(f)).

8. Ask if you are unsure. The FDA answers requests for classification information under section 513(g) of the Federal Food, Drug, and Cosmetic Act, for a fee. A notified body makes a “preliminary verification that the product is covered by this Regulation and its classification” before it quotes for an assessment (MDR Annex VII, Section 4.2(d)). The MHRA “can give advice if you are not sure which risk class your device falls into”.

9. Classify again after a change. A new intended purpose, a design change or a change to the rules can change the class. In the US, an exempt device needs a 510(k) when it meets a condition in its part’s .9 section, such as a new intended use (888.9(a)).

One device through the three systems: a cemented hip replacement

Intended purpose. To replace a hip joint, with a metal alloy femoral component and a polyethylene acetabular component, for use with bone cement.

The facts the rules depend on. It stays in the body after the operation, so it is an implant in all three systems. Its two components make up a total joint replacement. In this example it has no software, medicinal substance, tissues or cells, or nanomaterial.

US. Section 888.3350, the hip joint metal/polymer semi-constrained cemented prosthesis, matches its intended use and places it in class II. The section names no exemption, so the device needs a 510(k). In fiscal year 2027 the fee is $28,653, or $7,163 for a qualifying small business.

EU. Rule 8 puts implants in class IIb and names total or partial joint replacements as class III. The stricter sub-rule applies (Section 3.5), so the device is class III and a notified body assesses it (Article 52(3)). As a class III implant, it also needs four things: clinical investigations, unless Article 61(4) to (6) exempts it; the notified body’s clinical evaluation consultation procedure, unless Article 54(2) applies (Article 54(1)(a)); a summary of safety and clinical performance (Article 32); and a periodic safety update report, updated at least once a year (Article 86(1)).

Great Britain. Rule 8 of Annex IX gives class IIb. Directive 2005/50/EC puts the implantable components of a total hip replacement system in class III, so an approved body assesses the device (regulation 13(4)). On its CE marking under the EU MDR, its EU route counts in Great Britain until 30 June 2030, if the maker meets regulation 19C(3).

The record. US: 888.3350, class II. EU: rule 8, class III. Great Britain: rule 8 with Directive 2005/50/EC, class III.

How the FDA classifies medical devices: class I, II and III

Part 860 of Title 21 of the US Code of Federal Regulations (CFR) sets out how devices get their class. It defines each class by the controls the device needs:

Class I means the class of devices that are subject only to the general controls authorized by or under sections 501 (adulteration), 502 (misbranding), 510 (registration), 516 (banned devices), 518 (notification and other remedies), 519 (records and reports), and 520 (general provisions) of the Federal Food, Drug, and Cosmetic Act.

Class II means the class of devices that is or eventually will be subject to special controls.

Class III means the class of devices for which premarket approval is or will be required in accordance with section 515 of the Federal Food, Drug, and Cosmetic Act.

21 CFR 860.3

A device goes in class II “if general controls alone are insufficient to provide reasonable assurance of its safety and effectiveness and there is sufficient information to establish special controls”. Special controls include “performance standards, performance testing, postmarket surveillance, patient registries” and guidelines (860.3).

How to find a device’s class in the US

The FDA has established classifications for “approximately 1,700 different generic types of devices” and grouped them into 16 medical specialty panels. They are in Parts 862 to 892 of Title 21. Each section there, a classification regulation, gives the “identification (general description and intended use) and classification (class I, II or III)” of a device type or a few related types (860.3). Section 880.2920, for example, describes the clinical mercury thermometer and places it in class II.

The class depends on the intended use. The agency’s page Classify Your Medical Device says: “Device classification depends on the intended use of the device and also upon indications for use.” It adds that indications for use “can be found in the device’s labeling, but may also be conveyed orally during sale of the product.”

Implants and devices that support or sustain life go in class III by default:

The Commissioner will classify an implant or life-supporting or life-sustaining device into class III unless the Commissioner determines that such classification is not necessary to provide reasonable assurance of the safety and effectiveness of the device.

21 CFR 860.10(b)

A new type of device, with no classification regulation and no earlier device to compare it with, is in class III by statute. Section 860.84(a) refers to devices “classified into class III by statute under section 513(f)(1)” of the Federal Food, Drug, and Cosmetic Act. The agency’s De Novo page calls the request a “Request for Evaluation of Automatic Class III Designation”. Through a De Novo request, the maker asks for “classification into class I or class II for devices for which there is no legally marketed device on which to base a review of substantial equivalence” (860.200(a)).

The agency can change a device type’s class by an administrative order (860.130(c)), and the change reaches every device of that type: “The reclassification of any device within a generic type of device causes the reclassification of all devices within that generic type.” (860.120(b))

The US classes and the route to market for each

Most class I devices need no 510(k): the Classify Your Medical Device page says “Approximately 572 or 74% of the Class I devices are exempt from the premarket notification process.” The classification regulation names any exemption, as 880.2920 does for the clinical mercury thermometer. Class III devices take premarket approval (PMA) under Part 814; the agency’s PMA page says a class III device type that was on the market before the 1976 amendments still takes a 510(k) where the regulation states that “No effective date has been established of the requirement for premarket approval”.

An exemption has limits, set in each panel part’s .9 section (step 9 above). Exempt devices still follow the other general controls. The agency’s panels page says: “However, other General Controls such as registration and listing, labeling, and good manufacturing practices apply.”

The class also sets which US quality rules apply. The agency’s 510(k) page says makers of “Class II and III devices and select Class I devices” must meet the design and development requirements of ISO 13485, Clause 7.3, as 21 CFR 820 incorporates it. Our guide to ISO 13485 and 21 CFR Part 820 covers those requirements.

What to do. Find the classification regulation whose identification matches your device’s intended use, through the Product Code Classification Database or the panel’s part of Title 21, and check any exemption against that part’s .9 section. If no regulation matches and no legally marketed device is substantially equivalent, plan for a De Novo request or premarket approval.

Evidence to keep. The classification regulation and product code, with a note of why the device fits the regulation’s identification; for an exempt device, a check against each limit in the .9 section.

How the EU MDR classifies medical devices: class I, IIa, IIb and III

Article 51 of the EU Medical Device Regulation, Regulation (EU) 2017/745, sets four classes:

Devices shall be divided into classes I, IIa, IIb and III, taking into account the intended purpose of the devices and their inherent risks. Classification shall be carried out in accordance with Annex VIII.

Regulation (EU) 2017/745, Article 51(1)

The regulation defines the intended purpose as the use for which a device is intended “according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation” (Article 2(12)).

How Annex VIII works

Annex VIII has three chapters: definitions, implementing rules and the 22 classification rules. The definitions start with how long a device stays in continuous use: “transient” means under 60 minutes, “short term” 60 minutes to 30 days and “long term” over 30 days (Section 1). Article 2(4) adds: “Software shall also be deemed to be an active device”.

The implementing rules in Chapter II set how to apply the rules:

  • Accessories “shall be classified in their own right separately from the device with which they are used” (Section 3.2).
  • Software that drives a device or influences its use “shall fall within the same class as the device”; software independent of any other device “shall be classified in its own right” (Section 3.3).
  • When several rules apply, the strictest sets the class:

If several rules, or if, within the same rule, several sub-rules, apply to the same device based on the device’s intended purpose, the strictest rule and sub-rule resulting in the higher classification shall apply.

Regulation (EU) 2017/745, Annex VIII, Section 3.5

The 22 rules of Annex VIII

RuleWhat it coversClasses it gives
1Non-invasive devices that no other rule coversI
2Non-invasive devices for channelling or storing blood, body liquids, cells, tissues, liquids or gases for infusion, administration or introduction into the bodyI or IIa; blood bags IIb
3Non-invasive devices that modify the biological or chemical composition of tissues, cells, blood or other liquids for implantation or administration; substances used in vitro in direct contact with human cells, tissues, organs or embryosIIa or IIb; III for those substances
4Non-invasive devices that touch injured skin or mucous membraneI, IIa or IIb
5Devices invasive through a body orifice, other than surgically invasive devicesI, IIa or IIb, by duration of use and by connection to an active device
6Surgically invasive devices for transient useIIa; I for reusable surgical instruments; IIb or III in named cases
7Surgically invasive devices for short-term useIIa; IIb or III in named cases
8Implantable devices and long-term surgically invasive devicesIIb; IIa if placed in the teeth; III in named cases, among them active implantable devices, breast implants, surgical meshes, joint replacements and spinal disc replacements
9Active therapeutic devices that administer or exchange energy, and devices that control themIIa or IIb; III for devices that control active implantable devices
10Active devices for diagnosis and monitoringI, IIa or IIb
11SoftwareI, IIa, IIb or III
12Active devices that administer or remove medicinal products, body liquids or other substancesIIa or IIb
13Active devices that no other rule coversI
14Devices that incorporate a medicinal substance with an action ancillary to the device’sIII
15Devices for contraception or for preventing sexually transmitted diseasesIIb; III if implantable or long-term invasive
16Devices for contact lens care, and devices for disinfecting or sterilising devicesIIa or IIb
17Devices for recording X-ray diagnostic imagesIIa
18Devices made with non-viable tissues or cells of human or animal originIII, except animal-derived devices that touch intact skin only
19Devices that incorporate or consist of nanomaterialIIa, IIb or III, by the potential for internal exposure
20Body-orifice devices that administer medicinal products by inhalationIIa or IIb
21Devices made of substances that are introduced through a body orifice or applied to the skin, and absorbed or locally dispersed in the bodyIIa, IIb or III
22Active therapeutic devices with an integrated or incorporated diagnostic function that significantly determines patient managementIII

Rule 11, the rule for software, reads in full:

Software intended to provide information which is used to take decisions with diagnosis or therapeutic purposes is classified as class IIa, except if such decisions have an impact that may cause:

  • death or an irreversible deterioration of a person’s state of health, in which case it is in class III; or
  • a serious deterioration of a person’s state of health or a surgical intervention, in which case it is classified as class IIb.

Software intended to monitor physiological processes is classified as class IIa, except if it is intended for monitoring of vital physiological parameters, where the nature of variations of those parameters is such that it could result in immediate danger to the patient, in which case it is classified as class IIb.

All other software is classified as class I.

Regulation (EU) 2017/745, Annex VIII, Section 6.3, Rule 11

If a maker and its notified body disagree on the class, Article 51(2) sends the dispute “for a decision to the competent authority of the Member State in which the manufacturer has its registered place of business”. The European Commission lists the Medical Device Coordination Group’s (MDCG) guidance on classification, MDCG 2021-24, revision 1, dated April 2026, among its guidance documents.

What to do. Test the device against all 22 rules, with the facts from step 3 above, and keep the highest class any of them gives.

Evidence to keep. Annex II, Section 1.1(f), requires the technical documentation to contain “the risk class of the device and the justification for the classification rule(s) applied in accordance with Annex VIII”. Keep each rule you tested, with its result and the reason.

How the MHRA classifies medical devices in Great Britain

The MHRA’s guidance, Regulating medical devices in the UK, says: “Great Britain is England, Wales and Scotland.” In Northern Ireland the EU rules above apply. The same guidance says: “Since 26 May 2021, the EU Medical Devices Regulation (Regulation 2017/745) (EU MDR) has applied in EU Member States and Northern Ireland.”

For the purposes of this Part and Part VI, devices are classified as belonging to Class I, IIa, IIb or III in accordance with the classification criteria set out in Annex IX of Directive 93/42, read with Directive 2003/12 and Directive 2005/50.

The Medical Devices Regulations 2002, regulation 7(1)

The UK MDR 2002 define Directive 93/42 as the directive “as it had effect immediately before IP completion day” (regulation 2(1)), which was 31 December 2020 at 11pm (European Union (Withdrawal Agreement) Act 2020, section 39(1)).

Annex IX sets the same kind of implementing rules as the EU annex. The intended purpose governs (Section 2.1), accessories take their own class (Section 2.2), and “the strictest rules resulting in the higher classification shall apply” (Section 2.5).

For software, Annex IX says that software which drives a device or influences its use “falls automatically in the same class” (Section 2.3), and that “Stand alone software is considered to be an active medical device” (Section 1.4). It has no rule of its own for software.

Regulation 7 names two directives that move devices up to class III. Directive 2003/12/EC says “breast implants shall be reclassified as medical devices falling within Class III” (Article 1). Directive 2005/50/EC does the same for “hip, knee and shoulder replacements” (Article 1), which it defines as “an implantable component part of a total joint replacement system”, excluding “Ancillary components (screws, wedges, plates and instruments)” (Article 2).

Active implantable devices and in vitro diagnostic devices are outside the four classes. The agency’s guidance on the legal requirements in Great Britain says: “Active implantable devices are considered a separate risk class to general medical devices.” Part III of the UK MDR 2002 covers them and their accessories (regulation 21(1)), and Part IV covers in vitro diagnostic devices.

A dispute between a maker and its approved body over the class goes to the Secretary of State (regulation 7(2)).

What to do. Classify the device under Annex IX’s 18 rules and the two reclassification directives, and keep the GB class, its rule and the reason beside the EU class, in the technical documentation for the UK Conformity Assessed (UKCA) marking. Where the two classes differ, the table below shows which rule causes it.

Where Great Britain’s rules and the EU’s rules differ, rule by rule

Most of the EU’s 22 rules have a counterpart among Great Britain’s 18, often under a different number. The table pairs them, with our reading of what the EU text adds or changes; the annexes’ own text decides a device’s class. EU rules 1, 5, 12 to 15 and 17 give the same classes as GB rules 1, 5, 11 to 14 and 16, so the table leaves them out. Where an EU rule names a class III case that Great Britain’s rules lack, the device takes the class the GB rule otherwise gives, with two exceptions. Great Britain regulates active implantable devices and their accessories outside Annex IX (Part III of the UK MDR 2002), and products incorporating or derived from human tissues or cells are outside the UK MDR 2002 altogether (regulation 3(d)). Otherwise, in every row below except rule 18, the EU class can be higher than the GB class; under EU rule 16 it can also be lower, for some devices that disinfect invasive devices.

EU rule (Annex VIII)GB rule (Annex IX of Directive 93/42/EEC)What the EU text adds or changes
22 and 18Adds cells to what the devices channel or store. Blood bags are class IIb in both: under rule 2 in the EU and rule 18 in Great Britain
33Adds human tissues and cells to what the devices modify; puts substances used in vitro in direct contact with human cells, tissues, organs or embryos in class III
44Adds injured mucous membrane beside injured skin, and covers invasive devices that touch injured mucous membrane
66Class III for any device intended specifically for use in direct contact with the heart or the central circulatory system. Both rules put devices that control, diagnose, monitor or correct a defect of the heart or central circulatory system through direct contact in class III; for other direct contact, Great Britain’s rule names the central nervous system only
77The same addition as rule 6
88, with Directives 2003/12/EC and 2005/50/ECClass III for active implantable devices (outside Annex IX in Great Britain, under Part III of the UK MDR 2002), surgical meshes, all total or partial joint replacements, spinal disc replacements and implantable devices that touch the spinal column. Great Britain reclassifies only breast implants and the implantable components of total hip, knee and shoulder replacement systems; other implants take rule 8’s class IIb unless another part of the rule applies
99Class IIb for active devices that emit ionising radiation for therapy; class III for devices that control, monitor or directly influence active implantable devices. In Great Britain, accessories to active implantable devices fall under Part III of the UK MDR 2002 (regulation 21(1)), outside Annex IX
1010Class IIb for diagnosis in clinical situations where the patient is in immediate danger; widens the class IIb radiology paragraph from interventional radiology to all diagnostic or therapeutic radiology
11NoneA rule for software. In Great Britain, stand-alone software counts as an active device (Section 1.4), so rules 9 to 12 apply, and rule 12 puts any active device that no other rule covers in class I
1615Adds devices for sterilising devices. Class IIb covers disinfecting solutions and washer-disinfectors for invasive devices at the end point of processing; Great Britain’s rule puts any device specifically for disinfecting invasive devices in class IIb
1817Adds tissues and cells of human origin. In Great Britain, products incorporating or derived from human tissues or cells are outside the UK MDR 2002 (regulation 3(d)), and rule 17 covers non-viable animal tissues only
19NoneNanomaterial: IIa, IIb or III
20NoneMedicinal products given by inhalation: IIa or IIb
21NoneSubstances absorbed or locally dispersed in the body: IIa, IIb or III
22NoneActive therapeutic devices with an integrated diagnostic function, such as closed loop systems or automated external defibrillators: III

What each class requires before a device goes on sale

In both the EU and Great Britain, the class decides whether an outside body checks the device before it goes on sale, and how much of it the body checks. Class I makers declare conformity themselves; from class IIa up, a notified body in the EU or an approved body in Great Britain takes part. The US routes are in the FDA section above.

ClassEU (Article 52)Great Britain, UKCA marking (regulation 13)
IThe maker draws up the technical documentation and declares conformity (Article 52(7))The maker declares conformity under Annex VII (regulation 13(1))
I, sterile or with a measuring functionA notified body checks only the sterile or metrological aspects (Article 52(7)(a) and (b))An approved body checks only the sterility or metrology aspects (Annex VII, Section 5)
I, reusable surgical instrumentsA notified body checks the reuse aspects: cleaning, disinfection, sterilisation, maintenance, functional testing and the instructions for use (Article 52(7)(c))The maker declares conformity; Annex VII, Section 5, calls in an approved body only for sterile devices and devices with a measuring function
IIaA notified body audits the quality management system and assesses the technical documentation of a representative device in each category (Annex IX, Chapters I and III, and Section 4), or the Annex XI route (Article 52(6))An approved body audits the full quality assurance system (Annex II without Section 4); or the maker declares conformity under Annex VII and an approved body checks it under Annex IV, V or VI (regulation 13(2))
IIbAs class IIa, per generic device group, and for every class IIb implantable device except those listed (Annex IX, Chapters I and III, and Section 4); or type examination with product conformity verification (Annexes X and XI) (Article 52(4))An approved body audits the full quality assurance system (Annex II without Section 4); or it carries out type examination (Annex III) with a check under Annex IV, V or VI (regulation 13(3))
IIIA notified body audits the quality management system and assesses the technical documentation (Annex IX); or type examination with product conformity verification (Annexes X and XI) (Article 52(3))An approved body audits the full quality assurance system and examines the design dossier (Annex II); or it carries out type examination (Annex III) with a check under Annex IV or V (regulation 13(4))

A device CE marked under the EU MDR can also go on the GB market. When the maker meets regulation 19C(3), which includes following the EU route in Article 52, regulation 19C(2) treats regulation 13 as met, so the EU class sets the assessment for both markets. Regulation 1ZA(2) ends regulation 19C “at 23:59 on 30 June 2030”. These makers still have GB duties: the government’s response of 21 October 2026 names “appointment of a UK responsible person, MHRA registration, and post-market surveillance (PMS) obligations”.

What each class costs in fees, time, clinical evidence and reports

In the US, the FDA charges a fee for most submissions, set for each fiscal year in the Federal Register. For fiscal year 2027, which runs from 1 October 2026 to 30 September 2027, the fees are:

SubmissionStandard feeSmall business fee
510(k) premarket notification$28,653$7,163
De Novo classification request$191,020$47,755
Premarket approval application (PMA)$636,732$159,183
513(g) request for classification information$8,596$4,298
Annual fee for periodic reporting on a class III device$22,286$5,572

A business whose gross receipts or sales, with its affiliates, are “no more than $100 million for your most recent tax year” may qualify for the small business fees. To claim them, it sends the FDA its evidence at least 60 days before the fee is due. Most establishments pay an annual registration fee, $13,785 for fiscal year 2027, whatever their devices’ class.

The Federal Food, Drug, and Cosmetic Act sets the review periods. Under it, the FDA decides on a 510(k) “not later than 90 days after receiving the report” (section 510(n)(1)), classifies a device after a De Novo request “within 120 days” (section 513(f)(2)(A)(iii)), and acts on a PMA “in no event later than one hundred and eighty days after the receipt of an application”, with exceptions (section 515(d)(1)(A)). Questions add time: the agency’s De Novo page says that when it sends an Additional Information letter, “the De Novo request will be placed on hold”.

In the EU, notified bodies set their own fees. Article 50 says: “Notified bodies shall establish lists of their standard fees for the conformity assessment activities that they carry out and shall make those lists publicly available.”

The class also sets the clinical evidence. Article 61(4) says: “In the case of implantable devices and class III devices, clinical investigations shall be performed”. It exempts a modified version of the maker’s own marketed device that meets the paragraph’s conditions, and Article 61(5) and (6) add other cases. A notified body also follows a clinical evaluation consultation procedure for “class III implantable devices” and for “class IIb active devices intended to administer and/or remove a medicinal product” (Article 54(1)).

After sale, the class sets the reports. Class I makers prepare a post-market surveillance report (Article 85). Makers of class IIa, IIb and III devices prepare a periodic safety update report, updated “at least annually” for class IIb and III and “at least every two years” for class IIa (Article 86(1)). “For implantable devices and for class III devices, other than custom-made or investigational devices”, the maker also draws up a summary of safety and clinical performance (Article 32(1)).

What a wrong class costs

A class too low. The device goes on sale without the checks its class needs. In the US, a class III device without premarket approval “may not be marketed”. When the agency declines a De Novo request, “the device remains in class III and the requester may not legally market the device” (the De Novo page). In the EU, when a competent authority finds that a device does not comply and presents no unacceptable risk, it “shall require the relevant economic operator to bring the non-compliance concerned to an end within a reasonable period” (Article 97(1)); if the operator does not, the member state must restrict or prohibit the device or have it recalled or withdrawn (Article 97(2)). A device that presents an unacceptable risk falls under Article 95. In Great Britain, a device “may bear a UK marking only if” its maker has followed the route for its class (regulation 13). The MHRA’s borderline guidance says it reviews risk classification “if we become aware that a device which is on the market may have been misclassified”.

A class too high. The maker pays for checks the device did not need, and waits for them. In fiscal year 2027, a PMA costs $636,732 in FDA fees, against $28,653 for a 510(k).

A class found late. A notified body checks the class before it quotes and when it reviews the application (Annex VII, Sections 4.2(d) and 4.3(b)). A disagreement goes to the competent authority (Article 51(2)) or, in Great Britain, to the Secretary of State (regulation 7(2)). Step 8 above lists who answers early.

Dates and changes that affect a device’s class

The EU: devices still sold under the old directives

Makers can keep placing devices that hold certificates under the old directives on the EU market until dates that depend on the class:

Devices which have a certificate that was issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC and that is valid by virtue of paragraph 2 of this Article may be placed on the market or put into service until the following dates:

  1. (a) 31 December 2027, for all class III devices, and for class IIb implantable devices except sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors;
  2. (b) 31 December 2028, for class IIb devices other than those covered by point (a) of this paragraph, for class IIa devices, and for class I devices placed on the market in sterile condition or having a measuring function.
Regulation (EU) 2017/745, Article 120(3a)

A device whose maker declared conformity itself under Directive 93/42/EEC before 26 May 2021, and that needs a notified body under the MDR, has until 31 December 2028 (Article 120(3b)). This covers, for example, software that was class I under the directive and that rule 11 puts in class IIa or higher. All of these dates hold only if the maker and the device meet the conditions in Article 120(3c). Among them, the maker had to have a quality management system in place, and to have applied to a notified body, by 26 May 2024, and to have signed an agreement with it by 26 September 2024.

Great Britain: how long CE marked devices stay accepted

Regulation 1ZA of the UK MDR 2002 sets the end dates. The MHRA’s guidance, Regulating medical devices in the UK, gives them as follows:

  • devices under the old directives on medical devices (MDD) or active implantable devices (AIMDD): “up until the sooner of expiry of certificate or 30 June 2028”;
  • in vitro diagnostic devices under the old directive on them (IVDD): “up until the sooner of expiry of certificate or 30 June 2030”;
  • devices under the EU MDR, and in vitro diagnostic devices under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR): “up until 30 June 2030”.

On 21 October 2026, the government’s response to its consultation said it “intends to proceed with legislative changes to indefinitely recognise CE marked medical devices certified under EU MDR and EU IVDR, while aligning Great Britain transitional arrangements for EU MDD-compliant devices with EU timelines”. Until a change becomes law, the dates in regulation 1ZA stand.

Proposed changes to the classification rules

On 16 December 2025 the European Commission proposed changes to the MDR and the IVDR, COM(2025) 1023. Its explanatory memorandum says: “Some classification rules are adapted resulting in lower risk classes for certain devices, such as reusable surgical instruments, accessories to active implantable devices and software.” Its annex replaces rule 11 and amends other rules. The proposal is not law: the consolidated text of 9 November 2026 lists no act adopted from it.

On 8 May 2026 the MHRA published the draft Medical Devices (Amendment) Regulations 2026 on the World Trade Organisation’s notification portal. Its news release lists among their aims to “align classifications of in vitro diagnostic (IVD) devices with those of the International Medical Device Regulators Forum (IMDRF) standards”. The release names no change to the classes of other devices, and gives no date for the regulations to apply.

Questions about medical device classes

What are the 3 classes of medical devices?

In the US, class I holds the devices with the lowest risk and class III those with the greatest, in the FDA’s words, with class II between them. Class I devices need general controls only, class II devices need general and special controls, and class III devices need general controls and premarket approval. The EU and Great Britain use four classes: I, IIa, IIb and III.

What is a class 2 medical device?

In the US, class II is between the lowest-risk class I and the highest-risk class III. It holds the devices for which “general controls alone are insufficient to provide reasonable assurance of its safety and effectiveness”, so they also need special controls (21 CFR 860.3). Most need a 510(k). Examples from the regulations include the clinical mercury thermometer (880.2920), medical image management and processing systems (892.2050) and cemented metal and polymer hip replacements (888.3350). The EU and Great Britain divide the middle of the range into class IIa and class IIb.

What is a class 1 medical device?

In the US, class I holds the devices with “the lowest risk”. They need general controls only, and most need no 510(k): the manual toothbrush (872.6855) and the tongue depressor (880.6230) are two examples. In the EU and Great Britain, the maker of a class I device declares conformity itself, and an outside body checks only aspects such as sterility. The MHRA calls class I “generally regarded as low risk”.

What is a class 3 medical device?

In the US, class III holds the devices with the greatest risk, in the FDA’s words: those “for which premarket approval is or will be required” (21 CFR 860.3), such as the implantable pacemaker pulse generator (870.3610) or the silicone gel-filled breast prosthesis (878.3540). In the EU and Great Britain, class III is the highest of four classes, and every route to market for it, other than for custom-made devices, needs a notified body or an approved body (Article 52(3); regulation 13(4)).

What is the difference between class IIa and class IIb?

The MHRA’s guidance on borderline products calls class IIa “lower medium risk” and class IIb “higher medium risk”. The rules decide which a device falls in: under rule 5 of both the EU and GB annexes, for example, a device that enters a body orifice is class IIa for short-term use and class IIb for long-term use, with exceptions.

How do I find out what class my medical device is?

Write down the intended purpose and the facts the rules depend on, such as how long the device stays in use and whether it is an implant. In the US, search the FDA’s Product Code Classification Database, or the classification regulations in Parts 862 to 892 of Title 21, for the one that matches the intended use. In the EU, test the device against the 22 rules in Annex VIII of the MDR, and in Great Britain against the 18 rules in Annex IX of Directive 93/42/EEC; in both, the strictest rule sets the class. If you are unsure, the FDA answers requests under section 513(g), for a fee, and the MHRA gives advice.

Is a device’s class the same in the EU and the UK?

Northern Ireland applies the EU MDR, so the EU class holds there. Great Britain classifies under Annex IX of Directive 93/42/EEC, which has no rules for software, nanomaterial, inhaled medicinal products, substance-based devices or active therapeutic devices with an integrated diagnostic function, and fewer class III cases for implants. So the GB class can differ. A device CE marked under the EU MDR can use its EU class and route in Great Britain until 30 June 2030 (regulations 19C and 1ZA).

How are in vitro diagnostic devices classified?

In the EU, Regulation (EU) 2017/746 divides them “into classes A, B, C and D” (Article 47(1)). In Great Britain, Part IV of the UK MDR 2002 sorts them into general devices, self-test devices, and the devices on List B and List A of Annex II of Directive 98/79/EC. The draft GB regulations of 2026 aim to align these classifications with the International Medical Device Regulators Forum’s standards. In the US, they take the same three classes as other devices, in Parts 862, 864 and 866.

All guides

Sources

United States

European Union

Great Britain

General information, not legal advice. We read every source above in November 2026 and check them each month; the date at the top of the page shows the last review.